A STAT+ report raised the question of whether the US Treasury will tighten restrictions on investment in the Chinese biotech sector as financial policy and national security priorities converge. The focus is on how evolving rules could limit capital flows and affect cross-border dealmaking. This comes as US firms and investors already contend with complex compliance requirements tied to China exposure, and as market participants seek clarity on whether the next move is incremental guidance or a substantive restriction. For biotech companies planning partnerships, licensing, or capital strategy involving China, the risk is not just cost of capital—it’s deal timing and the ability to close transactions under changing constraints.